LIVOGIVA

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland

Active ingredients

The drug LIVOGIVA contains one active pharmaceutical ingredient (API):

1 Teriparatide UNII 10T9CSU89I - TERIPARATIDE

Teriparatide (rhPTH(1-34)) is the active fragment (1-34) of endogenous human parathyroid hormone. Teriparatide is a bone formation agent to treat osteoporosis. The skeletal effects of teriparatide depend upon the pattern of systemic exposure. Read about Teriparatide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIVOGIVA Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H05AA02	Teriparatide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05A Parathyroid hormones and analogues → H05AA Parathyroid hormones and analogues
Discover more medicines within H05AA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1826210, 1826221
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1201462001
Country: FR	Base de données publique des médicaments	Identifier(s): 65852307
Country: IT	Agenzia del Farmaco	Identifier(s): 048971016, 048971028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091064, 1091065
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100440233